Invivyd, Inc. is dedicated to protecting immunocompromised individuals from serious viral infectious diseases, starting with SARS-CoV-2. With over 9 million immunocompromised people in the United States, Invivyd aims to make a significant impact using its proprietary INVYMAB™ platform, which integrates advanced viral surveillance and predictive modeling with cutting-edge antibody engineering. This innovative approach enables the rapid development of new monoclonal antibodies (mAbs) to safeguard vulnerable populations. The team at Invivyd is composed of diverse professionals who are driven by a shared commitment to save lives, embrace creativity and adaptability, and view challenges as opportunities for growth and improvement. If you are looking to contribute to meaningful work in the biopharmaceutical landscape, Invivyd offers a collaborative and inclusive environment where your efforts can make a genuine difference.